Merck & Co Inc Merck’s (NYSE: MRK) Molnupiravir Shows Reduction In Virus Infection Merck & Co., Inc. (NYSE: MRK) has reported positive results from its Phase 2a to assess the safety of Molnupiravir. MRK is developing Molnupiravir jointly with Ridgeback Bio.
